Agenus Announces Ovarian Cancer Trial Results

Agenus Inc. reported three-year follow-up results from its Phase 1b C-800-01 trial for recurrent ovarian cancer patients.

48% Three-Year Survival Rate

Three-year overall survival remained at 48% for patients who received at least one dose of treatment.

Heavily Pretreated Patient Population

Patients had received a median of four prior lines of therapy, with 66% having at least four treatments.

Platinum-Resistant Disease Subset

Nearly three-quarters of patients had platinum-resistant or refractory ovarian cancer, meaning their cancer progressed during platinum treatment.

Durable Clinical Benefit

The survival plateau suggests durable clinical benefit for patients who had already received multiple treatments.

Dr. Porter's Perspective

Dana-Farber Cancer Institute's Dr. Rebecca L. Porter noted the survival plateau in heavily pretreated patients.

“What stands out with longer follow-up is the survival plateau in patients who had already received multiple treatments.”

BOT+BAL Combination Results

BOT+BAL achieved 23% objective response rate with one complete and seven partial responses.

Long-Term Survival in Refractory Cases

Patients with platinum-resistant disease showed 47% three-year survival and 20% objective response rate.

Treatment Strategy Implications

The results suggest BOT+BAL may be most effective before surgery to reduce recurrence and increase cure rates.